Share on StockTwits
 

Mylan (NYSE:MYL)’s share price reached a new 52-week high during trading on Wednesday, Analyst Ratings News reports. The stock traded as high as $45.12 and last traded at $44.74, with a volume of 4,720,126 shares traded. The stock had previously closed at $42.98.

A number of analysts have recently weighed in on MYL shares. Analysts at RBC Capital initiated coverage on shares of Mylan in a research note to investors on Monday. They set an “outperform” rating and a $50.00 price target on the stock. Separately, analysts at Leerink Swann raised their price target on shares of Mylan to $50.00 in a research note to investors on Monday, November 25th. Finally, analysts at Zacks downgraded shares of Mylan from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, November 20th. They now have a $44.00 price target on the stock. One analyst has rated the stock with a sell rating, six have assigned a hold rating and thirteen have given a buy rating to the company. Mylan currently has a consensus rating of “Buy” and an average target price of $40.47.

In other Mylan news, Director Neil Dimick sold 5,813 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $43.15, for a total value of $250,830.95. Following the completion of the sale, the director now directly owns 32,136 shares in the company, valued at approximately $1,386,668. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Mylan has a 52 week low of $27.50 and a 52 week high of $44.73. The stock’s 50-day moving average is $42.88 and its 200-day moving average is $38.00. The company has a market cap of $17.125 billion and a price-to-earnings ratio of 28.26.

Mylan (NYSE:MYL) last posted its quarterly earnings results on Thursday, October 31st. The company reported $0.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.79 by $0.03. The company had revenue of $1.77 billion for the quarter, compared to the consensus estimate of $1.84 billion. During the same quarter in the previous year, the company posted $0.83 earnings per share. The company’s revenue for the quarter was down 1.9% on a year-over-year basis. On average, analysts predict that Mylan will post $2.87 earnings per share for the current fiscal year.

Mylan Inc (NYSE:MYL) is a fully integrated global pharmaceutical company that develops, licenses, manufactures, markets and distributes generic, branded generic and specialty pharmaceuticals.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.